Cannabidiol
Cannabidiol 300 mg daily for 4 weeks
general clinical supportive measuresLoading study record…
Loading study record…
The objective of this work is to monitor the level of stress and overload of a group of front-line health workers (physicians, nurses and physiotherapists) who will participate in the care of patients with COVID-19 at Hospital das Clínicas in Ribeirão Preto and its Emergency Unit (HCRP), for four weeks, and evaluate the cannabidiol - CBD's effectiveness in reducing stress for those who wish to use it.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2021-09-28
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
The Bonsai study is a two-arm, parallel-group, individually randomized (1:1 allocation ratio), controlled with general measures (supporting motivational videos, fitness videos), participant and investigator unblinded, evaluator by phone will be blinded, single-site superiority trial of oral CBD 300 mg daily for 28 days to prevent burnout and distress in health care workers dealing with SARS-CoV-2 exposure. At 28 days, there is an open-label extension wherein all participants are offered a 28 days course of CBD 300mg daily. The objective of this work is to monitor the level of stress and overload of a group of front-line health workers (physicians, nurses and physiotherapists) who will participate in the care of patients with COVID-19 at Hospital das Clínicas in Ribeirão Preto and its Emergency Unit (HCRP), for four weeks, and evaluate the CBD's effectiveness in reducing stress for those who wish to use it. This research intends to : 1. Assess the level of stress and emotional overload of front-line health workers (physicians, nurses and physiotherapists) during their performance in the pandemic caused by COVID-19. 2. Assess whether the daily use of CBD 300 mg, for four weeks, reduces the level of stress, during the period of performance of professionals in the care of patients with COVID-19. 3. Assess whether the daily use of CBD 300 mg, for four weeks, will modify inflammatory parameters, such as cytokines, measured from the serum of professionals in the care of patients with COVID-19. 4. Assess whether the daily use of CBD 300 mg, for four weeks, prevents depression, burnout and Acute Stress Disorder and PTSD. 5. Assess the possible adverse effects of using CBD
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
Cannabidiol 300 mg daily for 4 weeks
general clinical supportive measuresEligibility
primary outcomes
Time frame: Through study completion, over time during the study period (day 0-28)
To assess the emotional exhaustion dimension of the burnout syndrome, based on nine items, scored from 0 ("never") to 6 ("every day")
secondary outcomes
Time frame: Through study completion, over time during the study period (day 0-28)
brief measure for assessing generalized anxiety disorder
Time frame: Through study completion, over time during the study period (day 0-28)
Evaluate depressive symptoms o
Time frame: Through study completion, over time during the study period (day 0-28)
Laboratory parameters, including the change in proinflammatory cytokine concentrations
Time frame: Through study completion, over time during the study period (day 0-28)
Occurrence of side effects
Time frame: Through study completion, over time during the study period (day 0-28)
It is a self-report measure widely used to assess PTSD symptoms, according to the DSM-5 criteria. The reduced version of this instrument will be used (8 items)
Publications